Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and hyoscine butylbromide, an antispasmodic agent.
## Primary Indications
* Symptomatic relief of abdominal pain and cramps associated with gastrointestinal spasms.
* Painful menstruation (dysmenorrhea).
## Adult Dosing
* **Abdominal pain/cramps:** 1 tablet (mefenamic acid 250 mg / hyoscine butylbromide 10 mg) three times daily.
* **Dysmenorrhea:** 1 tablet (mefenamic acid 250 mg / hyoscine butylbromide 10 mg) three times daily, starting from the onset of pain and continuing for up to 3 days.
Maximum dose: Not explicitly defined for the combination, but individual component maximums should be considered (e.g., mefenamic acid 1500 mg/day).
## Pediatric Dosing
Mefenamic acid has pediatric dosing recommendations, but the combination product Meftal spas is **generally not recommended for children**. Mefenamic acid dosing in children is typically based on weight and indication, often requiring liquid formulations. Consult specific pediatric guidelines for mefenamic acid alone if a pediatric indication arises.
## Dose Adjustments
* **Renal impairment:** Use with caution. Mefenamic acid is renally excreted, and dose reduction may be necessary in severe impairment.
* **Hepatic impairment:** Use with caution. Mefenamic acid is metabolized in the liver.
## Contraindications
* Hypersensitivity to mefenamic acid, hyoscine butylbromide, or other NSAIDs.
* History of gastrointestinal bleeding or perforation related to NSAID use.
* Active peptic ulceration or history of recurrent peptic ulceration.
* Severe renal, hepatic, or cardiac failure.
* Conditions where anticholinergic agents are contraindicated (e.g., narrow-angle glaucoma, paralytic ileus, severe ulcerative colitis, toxic megacolon, myasthenia gravis, tachycardia).
* Pregnancy (third trimester).
## Adverse Effects
* **Mefenamic acid:** Gastrointestinal disturbances (dyspepsia, nausea, vomiting, diarrhea, constipation, abdominal pain, occult blood loss), dizziness, headache, rash, bronchospasm. Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke. Renal toxicity.
* **Hyoscine butylbromide:** Anticholinergic effects (dry mouth, blurred vision, urinary retention, constipation, tachycardia).
## Key Drug Interactions
* **Mefenamic acid:**
* Anticoagulants (e.g., warfarin): Increased risk of bleeding.
* Corticosteroids: Increased risk of GI ulceration and bleeding.
* Other NSAIDs/Aspirin: Increased risk of GI side effects.
* Diuretics, ACE inhibitors, ARBs: Reduced antihypertensive effect, increased risk of renal impairment.
* Lithium, Methotrexate: Increased serum levels and toxicity.
* **Hyoscine butylbromide:**
* Other anticholinergic drugs: Additive effects, increased risk of anticholinergic side effects.
* Dopamine antagonists (e.g., metoclopramide): Reduced efficacy of both drugs.
## Monitoring
* **Gastrointestinal symptoms:** Monitor for signs of bleeding or ulceration.
* **Renal function:** Baseline and periodic assessment, especially in patients with pre-existing renal disease or those on concomitant nephrotoxic agents.
* **Hepatic function:** Baseline and periodic assessment, especially in patients with liver disease.
* **Blood pressure:** Monitor for potential NSAID-induced hypertension.
## Clinical Pearls
* Due to the mefenamic acid component, this medication carries a risk of serious gastrointestinal bleeding, ulceration, and perforation, which can occur at any time during treatment.
* The hyoscine butylbromide component may mask symptoms of serious underlying conditions.
* Use the lowest effective dose for the shortest duration necessary.
* Caution is advised in elderly patients, who are at higher risk of adverse effects.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines for complete and up-to-date details before making clinical decisions.
